Skip to main content
Top
Published in: Critical Care 1/2011

Open Access 01-02-2011 | Poster presentation

Therapy with recombinant human antithrombin, heparin and tissue plasminogen activator improves survival and reduces ventilation days in a long-term ovine model of cutaneous burn and smoke inhalation injury

Authors: S Asmussen, Y Yamamoto, DL Traber, H Ito, R Cox, H Hawkins, LD Traber, D Herndon, P Enkhbaatar

Published in: Critical Care | Special Issue 1/2011

Login to get access

Excerpt

In this study we investigated the long-term effects of a combined therapy with recombinant human antithrombin (rhAT), heparin (hep) and tissue plasminogen activator (tPA) in our established model of acute lung injury, resulting from burn and smoke inhalation injury (BSII). We hypothesised that this triple therapy decreases the requirement of ventilation, reduces ventilation days and improves survival. …
Metadata
Title
Therapy with recombinant human antithrombin, heparin and tissue plasminogen activator improves survival and reduces ventilation days in a long-term ovine model of cutaneous burn and smoke inhalation injury
Authors
S Asmussen
Y Yamamoto
DL Traber
H Ito
R Cox
H Hawkins
LD Traber
D Herndon
P Enkhbaatar
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9600

Other articles of this Special Issue 1/2011

Critical Care 1/2011 Go to the issue